Alport Syndrome Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
The Alport syndrome pipeline drugs market research report includes an assessment of the disease epidemiology, leading marketed products, late-to-mid-stage pipeline products with Phase Transition Success Rate (PTSR), and Likelihood of Approval (LoA) for Alport syndrome. The report also analyzes the clinical and commercial landscapes of Alport syndrome, as well as an assessment of deals, future market catalysts, key market players, and the future competitive environment.
Alport syndrome (AS) is a genetically and phenotypically heterogeneous, progressive hereditary renal disease that is characterized by sensorineural hearing loss and ocular abnormalities.
Which are the key regions in the Alport syndrome pipeline drugs market?
The key regions in the Alport syndrome pipeline drugs market are Asia-Pacific, Europe and North America. Of all the trials initiated in Alport syndrome over the past 10 years, single-country trials were most numerous in the Asia-Pacific region.
Which are the key development stages in the Alport syndrome pipeline drugs market?
The key development stages in the Alport syndrome pipeline drugs market are pre-registration, phase I, phase II, preclinical, and discovery. Preclinical stage has the highest share amongst all the others.
Alport syndrome pipeline drugs market, by development stage
For more development stage insights, download a free report sample
Which are the key countries for clinal trials in the Alport syndrome pipeline drugs market?
The key countries for clinical trials in the Alport syndrome pipeline drugs market are the US, Germany, Spain, Japan, Australia, the UK, China, South Korea, France and Italy. The US is the leading country in terms of the number of trial sites utilized for Alport syndrome trials over the past 10 years.
Alport syndrome pipeline drugs market, by countries
For more country insights, download a free report sample
Which are the key molecule types in the Alport syndrome pipeline drugs market?
The key molecule types in the Alport syndrome pipeline drugs market are small molecule, oligonucleotide, and biologic. Small molecule has the highest share in the Alport syndrome pipeline drugs market.
Alport syndrome pipeline drugs market, by molecule types
For more molecule types insights, download a free report sample
Which are the key MoA in the Alport syndrome pipeline drugs market?
The key MoA in the Alport syndrome pipeline drugs market are receptor antagonist, enzyme inhibitor, protein and peptide activator, ion channel activator, biological factor inhibitor, protein and peptide inhibitor, genes, nucleic acid & related components inhibitor. Receptor antagonist has the highest number of pipeline products.
Alport syndrome pipeline drugs market, by MoA
For more MoA insights, download a free report sample
Which are the key RoA in the Alport syndrome pipeline drugs market?
The key RoA in the Alport syndrome pipeline drugs market are oral and injection. Oral has the highest number of pipeline products.
Alport syndrome pipeline drugs market, by RoA
For more RoA insights, download a free report sample
Which are the key sponsors in the Alport syndrome pipeline drugs market?
The key sponsors in the Alport syndrome pipeline drugs market are Reata Pharmaceutical Inc, Eegulus Therapeutics Inc, River 3 Renal Corp, Genzyme Corp, Universitaetsmedizin Goettingen, Shanghai Children’s Hospital, Chinook Therapeutics Inc, TMC Pharma Services Ltd, and Others. Of the clinical trials initiated by commercial sponsors in Alport syndrome over the past 10 years, Reata Pharmaceuticals and Regulus Therapeutics have the highest number of completed trials.
Alport syndrome pipeline drugs market, by sponsors
To know more about sponsors, download a free report sample
Market report overview
Key regions | Asia-Pacific, Europe and North America |
Key Countries | The US, Germany, Spain, Japan, Australia, the UK, China, South Korea, France and Italy |
Key Development Stage | Pre-Registration, Phase I, Phase II, Preclinical, and Discovery |
Key MoA | Receptor Antagonist, Enzyme Inhibitor, Protein and Peptide Activator, Lon Channel Activator, Biological Factor Inhibitor, Protein And Peptide Inhibitor, Genes, Nucleic Acid & Related Components Inhibitor |
Key RoA | Oral and Injection |
Key Molecule Types | Small Molecule, Oligonucleotide, and Biologic |
Key Sponsors | Reata Pharmaceutical Inc, Eegulus Therapeutics Inc, River 3 Renal Corp, Genzyme Corp, Universitaetsmedizin Goettingen, Shanghai Children’s Hospital, Chinook Therapeutics Inc, TMC Pharma Services Ltd, and Others |
Scope
GlobalData’s Alport Syndrome Marketed and Pipeline Drugs Assessment, Clinical Trials, Social Media and Competitive Landscape, 2022 Update combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
- Components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the Alport Syndrome market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Alport Syndrome market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Frequently asked questions
-
Which are the key regions in the Alport syndrome pipeline drugs market?
The key regions in the Alport syndrome pipeline drugs market are Asia-Pacific, Europe and North America.
-
Which are the key countries for clinical trials in the Alport syndrome pipeline drugs market?
The key countries for clinical trials in the Alport syndrome pipeline drugs market are the US, Germany, Spain, Japan, Australia, the UK, China, South Korea, France and Italy.
-
Which are the key molecule types in the Alport syndrome pipeline drugs market?
The key molecule types in the Alport syndrome pipeline drugs market are small molecule, oligonucleotide, and biologic.
-
Which are the key development stages in the Alport syndrome pipeline drugs market?
The key development stages in the Alport syndrome pipeline drugs market are pre-registration, phase I, phase II, preclinical, and discovery
-
Which are the key MoA in the Alport syndrome pipeline drugs market?
The key MoA in the Alport syndrome pipeline drugs market are receptor antagonist, enzyme inhibitor, protein and peptide activator, lon channel activator, biological factor inhibitor, protein and peptide inhibitor, genes, nucleic acid & related components inhibitor.
-
Which are the key RoA in the Alport syndrome pipeline drugs market?
The key RoA in the Alport syndrome pipeline drugs market are oral and injection.
-
Which are the key sponsors in the Alport syndrome pipeline drugs market?
The key sponsors in the Alport syndrome pipeline drugs market are Reata Pharmaceutical Inc, Eegulus Therapeutics Inc, River 3 Renal Corp, Genzyme Corp, Universitaetsmedizin Goettingen, Shanghai Children’s Hospital, Chinook Therapeutics Inc, TMC Pharma Services Ltd, and Others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.